CRISPR Therapeutics AG CRSP

Updated: 11 Sep 2026

NASDAQ | Biotech | Gene editing and biotechnology

No signal published yet

We already track CRISPR Therapeutics AG and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow CRISPR Therapeutics AG free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Gene editing and biotechnology
We're already tracking CRISPR Therapeutics AG — here are the latest events we've registered

Recent News

  • On August 28, 2026, CRISPR Therapeutics presented Phase 1a clinical data for its CTX310 gene-editing candidate at the ESC Congress, demonstrating durable reductions in triglycerides and LDL cholesterol. In August 2026, the company reported second-quarter financial results featuring $76 million in CASGEVY revenue following expanded FDA approval for pediatric patients.

What Firelda Watch includes for CRISPR Therapeutics AG

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of CRISPR Therapeutics AG will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Xbrane Biopharma AB (publ)
XBRANE
HOLD
SynAct Pharma AB
SYNACT
HOLD

Biotech

More companies in this sector

Want to follow CRISPR Therapeutics AG? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow CRISPR Therapeutics AG free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

CRISPR Therapeutics AG CRSP
CRISPR Therapeutics AG — follow and we'll monitor it
Follow CRISPR Therapeutics AG free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.